Cue Biopharma (NASDAQ:CUE) Stock Rating Upgraded by Zacks Research

Cue Biopharma (NASDAQ:CUE) was upgraded by equities researchers at Zacks Research to a “hold” rating in a report released on Monday, Zacks reports.

Other analysts also recently issued research reports about the company. Wall Street Zen downgraded Cue Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, August 23rd. B. Riley Financial initiated coverage on shares of Cue Biopharma in a report on Friday. They issued a “buy” rating and a $83.00 target price for the company. Finally, Weiss Ratings downgraded shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $83.00.

Cue Biopharma Stock Performance

NASDAQ CUE opened at $30.90 on Monday. The stock has a market capitalization of $224.33 million, a P/E ratio of -1.14 and a beta of 2.45. Cue Biopharma has a 1 year low of $4.97 and a 1 year high of $45.50. The business’s fifty day moving average is $29.16 and its two-hundred day moving average is $98.05.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.The company had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. On average, research analysts forecast that Cue Biopharma will post -32.12 earnings per share for the current year.

Insider Transactions at Cue Biopharma

In other news, CEO Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96. Following the transaction, the chief executive officer owned 705,995 shares in the company, valued at approximately $20,205,576.90. The trade was a 2.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sumita Ray sold 8,829 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $265,664.61. Following the transaction, the insider directly owned 118,545 shares in the company, valued at $3,567,019.05. The trade was a 6.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 72,715 shares of company stock valued at $2,041,555 over the last quarter. Company insiders own 14.56% of the company’s stock.

Institutional Trading of Cue Biopharma

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Cue Biopharma in the second quarter worth approximately $1,824,000. ADAR1 Capital Management LLC purchased a new position in Cue Biopharma during the second quarter valued at approximately $1,742,000. Citadel Advisors LLC increased its stake in Cue Biopharma by 301.8% in the 2nd quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock valued at $809,000 after buying an additional 38,333 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new position in Cue Biopharma in the 2nd quarter valued at approximately $722,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Cue Biopharma in the 2nd quarter worth approximately $389,000. 35.04% of the stock is owned by hedge funds and other institutional investors.

Key Cue Biopharma News

Here are the key news stories impacting Cue Biopharma this week:

• Positive Sentiment: Strong Phase 2 efficacy: CUE-221 met the primary goal in a CSU study, with 54% of patients achieving complete hive resolution after 12 weeks. The result was reported as statistically significant versus Xolair, with p<0.005, supporting the candidate’s potential as a differentiated treatment. Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
• Positive Sentiment: Large commercial opportunity and upcoming catalysts: Analysts highlighted CUE-221’s dual mechanism of action, its apparent efficacy relative to Xolair, and potential applications in CSU and food allergy. Investors may look ahead to 36-week pharmacokinetic and IgE data in 2026, followed by planned global Phase 2b/3 studies. Cue Biopharma: Initiating Buy Based on CUE-221 Trial Win
• Neutral Sentiment: Volatile market reaction: Coverage described an initial surge in CUE shares followed by swings as investors took profits. The unusually high trading volume reflects substantial repositioning after the clinical announcement rather than a new fundamental setback. Cue Biopharma Stock Swings After Positive CUE-221 Phase 2 Data
• Negative Sentiment: Execution and valuation risks remain: Despite the positive topline data, some coverage characterized the share-price decline after the initial rally as unwarranted, while the pullback underscores investor concerns about profit-taking, clinical-development risk, and the need to confirm durability in longer follow-up and later-stage trials. An Orexin Drug’s Proof of Concept in ADHD; Cue’s Unwarranted Share Slide

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company developing therapeutics that selectively activate and regulate antigen-specific T cells inside the body. Its approach is designed to direct the immune system toward cancer cells while potentially reducing the broad immune activation and toxicity associated with conventional immunotherapies.

The company’s proprietary Immuno-STAT (Selective Targeting of Antigens for Remodeling of T cells) platform uses biologic molecules that combine peptide-major histocompatibility complex components with immune-modulating signals.